Braveheart Posts Q3 Loss of $26.5M; $503.5M Cash Funds Runway Into 2029
BRVE sits 17% above its 52-week low of $16.7.
Summary
Braveheart reported a $26.5 million Q3 2026 net loss and $503.5 million in cash, enough to fund operations into 2029. The company said its nHCM Phase 3 and fixed-dose oHCM Phase 2b trials should start in the first half of 2027.
Key Events · Earnings and Guidance · BRVE
-
Q3 Loss Narrows to $26.5M
Net loss was $26.5 million, or $0.51 per share, versus $59.1 million a year earlier — a comparison inflated by a $58.8 million in-process R&D charge in the prior-year quarter.
-
Cash of $503.5M Funds Runway Into 2029
Cash, cash equivalents and investments stood at $503.5 million at September 30, 2026, up from $89.2 million at year-end 2025 following the August IPO.
-
Spending Ramps With Phase 3 Enrollment
R&D expense was $17.5 million and G&A $12.6 million for the quarter. G&A included $7.8 million of non-cash stock-based compensation, of which $6.1 million related to liability-classified awards remeasured each period.
-
Two Trials Slated for First Half 2027
The FDA end-of-Phase 2 meeting for NOBLEHEART-HCM is complete, and both NOBLEHEART-HCM (nHCM Phase 3) and TRUEHEART-HCM (fixed-dose oHCM Phase 2b) are planned to initiate in the first half of 2027.
Analysis · BRVE · Life Sciences
The quarter's headline is the balance sheet: $503.5 million in cash and investments after the August IPO funds operations into 2029, so there is no near-term financing need and no dilution overhang from this filing. Spending is ramping as expected. R&D rose to $17.5 million from essentially nothing a year ago as LIONHEART-HCM enrolls, and G&A hit $12.6 million, including $7.8 million of non-cash stock compensation. The net loss narrowed to $26.5 million from $59.1 million, but that comparison is flattered by a $58.8 million in-process R&D charge in the year-ago period, not by improving economics. On the pipeline, the FDA end-of-Phase 2 meeting for NOBLEHEART-HCM is done, and both NOBLEHEART and the fixed-dose TRUEHEART-HCM Phase 2b are slated to start in the first half of 2027. The LIONHEART interim LVOT analysis is expected in the second half of 2027 — a long gap before the next major readout.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRVE was trading at $19.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $16.70 to $32.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.